Facebook
Twitter
Telegram
Report an ErrorSyndax Pharmaceuticals Balance Sheet 2011-2024 | SNDX
Annual Balance Sheet Syndax Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-294 M | -73.2 M | -221 M | -97.1 M | -23.7 M | -33.8 M | -35.2 M | -23.8 M | -23.2 M | 3.88 M | -10.1 M | 20.8 M | - |
Long Term Debt |
578 K | 709 K | 711 K | 17.8 M | - | - | - | - | - | 7.44 M | - | - | - |
Long Term Debt Current |
1.04 M | 434 K | 361 K | 316 K | 478 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
588 K | 722 K | 20.6 M | 29.6 M | 13.6 M | 14.8 M | 17.1 M | 14.5 M | 18.4 M | 8.19 M | 2.48 M | 5.69 M | - |
Total Current Liabilities |
58.1 M | 29.1 M | 20.7 M | 18.9 M | 18.4 M | 16.1 M | 15.8 M | 10.4 M | - | - | - | - | - |
Total Liabilities |
58.7 M | 29.8 M | 41.3 M | 48.4 M | 31.9 M | 30.9 M | 32.9 M | 24.9 M | 23.2 M | 18.5 M | 5.21 M | 30.8 M | - |
Deferred Revenue |
- | - | - | - | 1.52 M | 1.52 M | 1.57 M | 1.22 M | 1.22 M | - | - | - | - |
Retained Earnings |
-902 M | -693 M | -544 M | -569 M | -495 M | -439 M | -366 M | -305 M | -260 M | -160 M | -136 M | -79.1 M | - |
Total Assets |
613 M | 497 M | 450 M | 301 M | 63.5 M | 83.9 M | 137 M | 109 M | 89.9 M | 12.8 M | 17.1 M | 1.51 M | - |
Cash and Cash Equivalents |
295 M | 74.4 M | 222 M | 115 M | 24.6 M | 33.8 M | 35.2 M | 23.8 M | 23.2 M | 10 M | - | - | - |
Book Value |
554 M | 467 M | 408 M | 252 M | 31.6 M | 53 M | 104 M | 84.1 M | 66.7 M | -5.72 M | 11.8 M | -29.3 M | - |
Total Shareholders Equity |
554 M | 467 M | 408 M | 252 M | 31.6 M | 53 M | 104 M | 84.1 M | -252 M | -153 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Syndax Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
327 K | 578 K | 851 K | 1.12 M | 588 K | 709 K | 768 K | 570 K | 643 K | 711 K | 798 K | 22 K | 60 K | 101 K | 101 K | 101 K | 101 K | 419 K | 419 K | 419 K | 419 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
334 K | 588 K | 864 K | 1.13 M | 600 K | 722 K | 782 K | 13.6 M | 17.1 M | 20.6 M | 11.8 M | 24.2 M | 26.9 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
51.1 M | 58.7 M | 40 M | 31.3 M | 24.3 M | 29.8 M | 21.6 M | 44.5 M | 47.7 M | 41.3 M | 40.5 M | 48.5 M | 51.5 M | 48.4 M | 48.4 M | 48.4 M | 48.4 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 32.9 M | 32.9 M | 32.9 M | 32.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 1.57 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-975 M | -902 M | -830 M | -779 M | -734 M | -693 M | -654 M | -618 M | -581 M | -544 M | -640 M | -619 M | -596 M | -569 M | -569 M | -569 M | -569 M | -495 M | -495 M | -495 M | -495 M | -439 M | -439 M | -439 M | -439 M | -366 M | -366 M | -366 M | -366 M | -305 M | -305 M | -305 M | -305 M | -260 M | -260 M | -260 M | -260 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
543 M | 613 M | 399 M | 431 M | 460 M | 497 M | 360 M | 406 M | 422 M | 450 M | 240 M | 263 M | 280 M | 301 M | 301 M | 301 M | 301 M | 63.5 M | 63.5 M | 63.5 M | 63.5 M | 83.9 M | 83.9 M | 83.9 M | 83.9 M | 137 M | 137 M | 137 M | 137 M | 109 M | 109 M | 109 M | 109 M | 89.9 M | 89.9 M | 89.9 M | 89.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
115 M | 295 M | 94.6 M | 97.3 M | 57.5 M | 74.4 M | 71.4 M | 120 M | 189 M | 222 M | 71.4 M | 68 M | 64.4 M | 115 M | 115 M | 115 M | 115 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 10 M | - | - | - | 10.1 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
492 M | 554 M | 359 M | 400 M | 436 M | 467 M | 338 M | 362 M | 375 M | 408 M | 199 M | 215 M | 228 M | 252 M | 252 M | 252 M | 252 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 53 M | 53 M | 53 M | 53 M | 104 M | 104 M | 104 M | 104 M | 84.1 M | 84.1 M | 84.1 M | 84.1 M | 66.7 M | 66.7 M | 66.7 M | 66.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
492 M | 554 M | 359 M | 400 M | 436 M | 467 M | 338 M | 362 M | 375 M | 408 M | 199 M | 215 M | 228 M | 252 M | 252 M | 252 M | 252 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 53 M | 53 M | 53 M | 53 M | 104 M | 104 M | 104 M | 104 M | 84.1 M | 84.1 M | 84.1 M | 84.1 M | -252 M | -252 M | -252 M | -252 M | -153 M | - | - | - | -128 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency